Early Peyronie's Disease Management
In the active/early phase of Peyronie's disease, prioritize pain control with NSAIDs or daily tadalafil 5 mg, counsel patients on natural history, and avoid oral therapies without proven efficacy—reserving intralesional treatments and penile traction for patients who progress beyond the initial inflammatory window. 1
Defining Active Disease
Active disease is the critical early window characterized by:
- Penile pain with or without erection (the defining symptom)
- Progressive or changing deformity
- Symptoms present for less than 6 months
- Plaque(s) may not be fully developed yet
- Curvature may still be evolving 2
This phase represents a potential therapeutic window where fibroblast-to-myofibroblast transformation is pharmacologically accessible, though clinical translation remains investigational 3.
Initial Management Strategy
Pain Control (First Priority)
- NSAIDs for active-phase penile pain 1
- Daily tadalafil 5 mg demonstrated lower curvature progression rates and improved symptoms versus controls, with evidence showing it may reduce collagen deposition and increase apoptosis 1
- Pain typically resolves spontaneously in most patients over time without intervention 2
Patient Counseling (Essential)
Discuss immediately:
- Natural history: pain often resolves; curvature less likely to improve (though younger men and those with symptoms <6 months may see some improvement) 2
- PD does not lead to malignancy 1
- Many patients achieve disease stabilization allowing acceptable sexual function 4
- Emotional distress and relationship difficulties are common and persistent 2
What NOT to Do Early
Avoid oral therapies without proven efficacy including pentoxifylline, vitamin E, tamoxifen, procarbazine, potassium para-aminobenzoate, omega-3 fatty acids, or combinations—these lack evidence and may delay more effective interventions 1, 2. The 2025 EAU guidelines explicitly state these are "not recommended due to a lack of proven efficacy" 1.
Critical Caveat on PDE5I/SERM Therapy
While PDE5 inhibitors and selective estrogen receptor modulators (SERMs like tamoxifen) show timing-dependent antifibrotic effects in experimental models, placebo-controlled monotherapy evidence remains negative or neutral for tamoxifen, especially when disease duration is broad 3. Current guidelines do not endorse PDE5I/SERM therapy as standard practice—it remains investigational 3.
When to Escalate Treatment
Reserve more aggressive interventions for patients who:
- Progress beyond 3-6 months with stable disease
- Develop curvature >30° that compromises sexual function
- Have intact erectile function (for intralesional therapy eligibility)
At that point, consider:
- Intralesional collagenase (if available) for curvature 30-90° with modeling 1, 2
- Penile traction therapy as adjunct (requires 2-8 hours daily use) 1
- Low-intensity extracorporeal shockwave therapy for pain relief (no effect on curvature) 1
Diagnostic Essentials in Early Phase
Perform:
- Careful history documenting onset, pain characteristics, deformity progression
- Physical exam with penile palpation (though plaques may not be palpable early)
- Reserve intracavernosal injection test with duplex ultrasound for before any invasive intervention, not routinely in early active phase 2
The Bottom Line
Early PD management is conservative and symptom-focused. The active phase may represent an antifibrotic treatment window, but no oral regimen has shown high-certainty disease-modifying efficacy 3. Focus on pain control, realistic expectations, and watchful waiting—many patients stabilize without aggressive intervention. Surgery requires stable disease for 3-6 months and is reserved for refractory cases 1.